Market closedNon-fractionalADR
Amarin/AMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Amarin
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Ticker
AMRN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Dublin, Ireland
Employees
275
Website
amarincorp.com
Amarin Metrics
BasicAdvanced
$355M
Market cap
-
P/E ratio
-$0.13
EPS
1.99
Beta
-
Dividend rate
Price and volume
Market cap
$355M
Beta
1.99
52-week high
$1.49
52-week low
$0.65
Average daily volume
27
Financial strength
Current ratio
3.066
Quick ratio
1.928
Management effectiveness
Return on assets (TTM)
-6.38%
Return on equity (TTM)
-9.30%
Return on investment (TTM)
-8.90%
Valuation
Price to revenue (TTM)
1.281
Price to book
0.651
Price to tangible book (TTM)
0.674
Price to free cash flow (TTM)
457.402
Growth
Revenue change (TTM)
-23.04%
Earnings per share change (TTM)
43.22%
3-year revenue growth (CAGR)
-20.64%
What the Analysts think about Amarin
Analyst Ratings
Majority rating from 4 analysts.
Amarin Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$57M
-24.36%
Net income
-$9.9M
73.68%
Profit margin
-17.52%
129.62%
Amarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.04
-$0.05
-$0.01
-$0.02
-
Expected
-$0.04
-$0.05
-$0.03
-$0.03
-$0.04
Surprise
14.29%
11.11%
-66.67%
-33.33%
-
Amarin News
AllArticlesVideos
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
GlobeNewsWire·1 week ago
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
GlobeNewsWire·1 week ago
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amarin stock?
Amarin (AMRN) has a market cap of $355M as of July 27, 2024.
What is the P/E ratio for Amarin stock?
The price to earnings (P/E) ratio for Amarin (AMRN) stock is 0 as of July 27, 2024.
Does Amarin stock pay dividends?
No, Amarin (AMRN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Amarin dividend payment date?
Amarin (AMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Amarin?
Amarin (AMRN) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Amarin stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.